ExodusPoint Capital Management LP Acquires New Holdings in Masimo Co. (NASDAQ:MASI)

ExodusPoint Capital Management LP purchased a new position in Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 25,426 shares of the medical equipment provider's stock, valued at approximately $4,203,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Verition Fund Management LLC purchased a new stake in shares of Masimo during the third quarter valued at $245,000. Stifel Financial Corp purchased a new position in shares of Masimo during the third quarter valued at $229,000. State Street Corp raised its position in Masimo by 0.7% during the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock valued at $191,837,000 after buying an additional 10,179 shares during the period. Two Sigma Advisers LP lifted its position in shares of Masimo by 95.9% in the third quarter. Two Sigma Advisers LP now owns 218,600 shares of the medical equipment provider's stock worth $29,146,000 after purchasing an additional 107,000 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new position in Masimo during the third quarter valued at approximately $499,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Stock Performance

Shares of MASI stock traded up $2.41 during mid-day trading on Friday, reaching $153.90. The stock had a trading volume of 729,386 shares, compared to its average volume of 655,434. The firm's 50 day simple moving average is $170.60 and its 200 day simple moving average is $164.27. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $8.32 billion, a PE ratio of 106.14 and a beta of 1.28. Masimo Co. has a one year low of $101.61 and a one year high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. On average, analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Piper Sandler upped their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Wells Fargo & Company upped their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Thursday. Finally, Raymond James upped their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Masimo presently has a consensus rating of "Moderate Buy" and an average price target of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.